Cargando…

Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo

BACKGROUND: Uterine sarcomas are very rare malignancies with no approved chemotherapy protocols. Histone deacetylase (HDAC) inhibitors belong to the most promising groups of compounds for molecular targeting therapy. Here, we described the antitumor effects of suberoylanilide hydroxamic acid (SAHA;...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hrzenjak, Andelko, Moinfar, Farid, Kremser, Marie-Luise, Strohmeier, Bettina, Petru, Edgar, Zatloukal, Kurt, Denk, Helmut
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843655/ https://www.ncbi.nlm.nih.gov/pubmed/20202195 http://dx.doi.org/10.1186/1476-4598-9-49

Ejemplares similares

JAZF1/SUZ12 gene fusion in endometrial stromal sarcomas
por: Hrzenjak, Andelko
Publicado: (2016)

Effect of histone deacetylase inhibitor (vorinostat) on new-onset diabetes induced by tacrolimus
por: Bakhdar, Fatmah A., et al.
Publicado: (2022)

Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
por: Saelen, Marie Grøn, et al.
Publicado: (2012)

Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells
por: Eto, Shotaro, et al.
Publicado: (2019)

Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines
por: Bernhart, Eva, et al.
Publicado: (2017)

Histone deacetylases inhibition by SAHA/Vorinostat normalizes the glioma microenvironment via xCT equilibration
por: Wolf, Ines M. L., et al.
Publicado: (2014)

Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells
por: Phillip, Cornel J, et al.
Publicado: (2012)

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021)

Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
por: O'Connor, O A
Publicado: (2006)

Brief Report: Case Comparison of Therapy With the Histone Deacetylase Inhibitor Vorinostat in a Neonatal Calf Model of Pulmonary Hypertension
por: Applegate, Tanya J., et al.
Publicado: (2021)

Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
por: Richon, V M
Publicado: (2006)

The Mechanism of Action of the Histone Deacetylase Inhibitor Vorinostat Involves Interaction with the Insulin-Like Growth Factor Signaling Pathway
por: Sarfstein, Rive, et al.
Publicado: (2011)

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
por: Munster, P N, et al.
Publicado: (2009)

The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression through Translational Inhibition
por: Hutt, Darren M., et al.
Publicado: (2014)

Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis
por: Laengle, Johannes, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors Romidepsin and Vorinostat Promote Hepatitis B Virus Replication by Inducing Cell Cycle Arrest
por: Yang, Yang, et al.
Publicado: (2021)

Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat
por: Maxwell, Jill W., et al.
Publicado: (2020)

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
por: LaBonte, Melissa J, et al.
Publicado: (2009)

Synergistic silencing of α-globin and induction of γ-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for β-thalassaemia
por: Mettananda, Sachith, et al.
Publicado: (2019)

Crafting Carbazole-Based Vorinostat and Tubastatin-A-like Histone Deacetylase (HDAC) Inhibitors with Potent in Vitro and in Vivo Neuroactive Functions
por: Reddy, R. Gajendra, et al.
Publicado: (2019)

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
por: Munster, P N, et al.
Publicado: (2011)

Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
por: Okabe, Seiichi, et al.
Publicado: (2014)

Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma
por: Yang, Qiwei, et al.
Publicado: (2022)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Priming, Triggering, Adaptation and Senescence (PTAS): A Hypothesis for a Common Damage Mechanism of Steatohepatitis
por: Abuja, Peter M., et al.
Publicado: (2021)

MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas
por: Fadejeva, Irina, et al.
Publicado: (2017)

Vorinostat—An Overview
por: Bubna, Aditya Kumar
Publicado: (2015)

Histone deacetylase 9 deficiency exaggerates uterine M2 macrophage polarization
por: Liu, Yanqin, et al.
Publicado: (2021)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial
por: Pili, Roberto, et al.
Publicado: (2017)

Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma
por: Kang, Dong Woo, et al.
Publicado: (2020)

Synergism of Heat Shock Protein 90 and Histone Deacetylase Inhibitors in Synovial Sarcoma
por: Nguyen, Anne, et al.
Publicado: (2009)

Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis
por: Schmidt, Oxana, et al.
Publicado: (2021)

Inhibition of histone deacetylation with vorinostat does not prevent tunicamycin-mediated acute kidney injury
por: Carlisle, Rachel E., et al.
Publicado: (2021)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Epigenetic Silencing of Apoptosis-Inducing Gene Expression Can Be Efficiently Overcome by Combined SAHA and TRAIL Treatment in Uterine Sarcoma Cells
por: Fröhlich, Leopold F., et al.
Publicado: (2014)

Causability and explainability of artificial intelligence in medicine
por: Holzinger, Andreas, et al.
Publicado: (2019)

Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells
por: Morgan, Sherif S, et al.
Publicado: (2014)

Correction to: Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis
por: Schmidt, Oxana, et al.
Publicado: (2022)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_080j3vukhvm3klq7rkgtno9vn8